93 related articles for article (PubMed ID: 9769394)
21. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.
Lauterburg BH; Nguyen T; Hartmann B; Junker E; Küpfer A; Cerny T
Cancer Chemother Pharmacol; 1994; 35(2):132-6. PubMed ID: 7987989
[TBL] [Abstract][Full Text] [Related]
22. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.
van Warmerdam LJ; Rodenhuis S; van Tellingen O; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1994; 35(2):179-81. PubMed ID: 7987998
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
Verschraagen M; Zwiers TH; Torun E; Donker MG; Reinhoud NJ; Van der Vijgh WJ
J Pharm Sci; 2003 May; 92(5):1040-50. PubMed ID: 12712424
[TBL] [Abstract][Full Text] [Related]
24. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
25. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Pendyala L; Schwartz G; Smith P; Zdanowicz J; Murphy M; Hausheer F
Cancer Chemother Pharmacol; 2003 May; 51(5):376-84. PubMed ID: 12682786
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
[TBL] [Abstract][Full Text] [Related]
27. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Verschraagen M; Boven E; Torun E; Hausheer FH; Bast A; van der Vijgh WJ
Biochem Pharmacol; 2004 Aug; 68(3):493-502. PubMed ID: 15242815
[TBL] [Abstract][Full Text] [Related]
28. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
Bokemeyer C; Schmoll HJ; Ludwig E; Harstrick A; Dunn T; Casper J
Br J Cancer; 1994 May; 69(5):863-7. PubMed ID: 8180015
[TBL] [Abstract][Full Text] [Related]
29. Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion.
Zhang Y; Kawedia JD; Myers AL; McIntyre CM; Anderson PM; Kramer MA; Culotta KS
J Oncol Pharm Pract; 2014 Feb; 20(1):51-7. PubMed ID: 23512269
[TBL] [Abstract][Full Text] [Related]
30. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
Leeuwenkamp OR; Neijt JP; van der Vijgh WJ; Pinedo HM
Eur J Cancer; 1991; 27(10):1243-7. PubMed ID: 1835593
[TBL] [Abstract][Full Text] [Related]
31. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
32. Mesna (2-mercaptoethane sodium sulfonate) functions as a regulator of myeloperoxidase.
Jeelani R; Jahanbakhsh S; Kohan-Ghadr HR; Thakur M; Khan S; Aldhaheri SR; Yang Z; Andreana P; Morris R; Abu-Soud HM
Free Radic Biol Med; 2017 Sep; 110():54-62. PubMed ID: 28552694
[TBL] [Abstract][Full Text] [Related]
33. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
34. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
[TBL] [Abstract][Full Text] [Related]
35. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
[TBL] [Abstract][Full Text] [Related]
36. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.
Sooriyaarachchi M; Narendran A; Gailer J
Metallomics; 2011 Jan; 3(1):49-55. PubMed ID: 21135941
[TBL] [Abstract][Full Text] [Related]
37. The fate of [14C]-mesna in the rat.
Shaw IC; Graham MI; Jones MS
Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
James CA; Mant TG; Rogers HJ
Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
[TBL] [Abstract][Full Text] [Related]
39. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]